Ausgabe Sonderheft 4/2010
Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection
Inhalt (290 Artikel)
Why suppression of HIV replication does not always make everything better
M Lederman
The public health implications of antiretroviral therapy – 2011 and beyond
KM De Cock
O111. The changing face of HIV resistance; HIV drug resistance north and south — what's next?
J Schapiro
O112. International perspectives on adherence and resistance to HIV antiretroviral therapy
D Bangsberg
O113. Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US
PE Sax, JL Meyers, MJ Mugavero, KL Davis
O114. Long-term probability of detecting drug-resistant HIV in patients starting antiretroviral therapy within the first year of HIV infection
S Lodi, C Kücherer, AM Bakken Kran, B Masquelier, A d'Arminio Monforte, J Gill, D Dunn, D Pillay, K Porter
O115. Low-level residual viremia and risk of virological failure
G Cologni, L Soavi, S Leone, D Valenti, A Callegaro, G Gregis, F Suter, F Maggiolo
O116. The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
A Pironti, A Sönnerborg, M Zazzi, R Kaiser, D Struck, B Clotet, ÀM Vandamme, F Incardona, T Lengauer, M Rosen-Zvi, M Prosperi
O121. Consensus statement of the European guidelines on clinical management of HIV-1 tropism testing
LPR Vandekerckhove, AMJ Wensing, R Kaiser, F Brun-Vezinet, B Clotet, A De Luca, S Dressler, F Garcia, AM Geretti, T Klimkait, K Korn, B Masquelier, CF Perno, J Schapiro, V Soriano, A Sönnerborg, ÀM Vandamme, C Verhofstede, H Walter, M Zazzi, CA Boucher
O122. Calibration and accuracy of the geno2pheno co-receptor algorithm for predicting HIV tropism for single and triplicate measurements of V3 genotype
LC Swenson, D Knapp, PR Harrigan
O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists
CJ Brumme, W Dong, D Chan, T Mo, LC Swenson, C Woods, J Demarest, J Heera, H Valdez, PR Harrigan
O124. Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients
E Seclén, M Gonzalez, L Martín-Carbonero, H Gellermann, V Cairns, M Distel, W Kadus, V Soriano, E Poveda
O125. Influence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patients
H Valdez, D Chapman, P Biswai, M Lewis, C Craig, J Heera, S Ellery, LC Swenson, PR Harrigan
O131. Treatment as prevention within the framework of current guidelines
J Montaner
O132. Treatment-as-prevention: stopping the epidemic of HIV
B Williams
O135. A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study
A Sönnerborg, A Mocroft, JD Lundgren, D Raben, J Gatell, A Vassilenko, V Hadziosmanovic, J Bergovac, H Sørensen, M Cusini, N Clumeck, B Gazzard, J Rockstroh, M Zuin, A D'Arminio Monforte
O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis
WFW Bierman, EH Humphreys, MA van Agtmael, CA Boucher, GW Rutherford
O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
N Clumeck, JR Arribas, P Pulick, G Fätkenheuer, A Hill, Y Van Delft, C Moecklinghoff
O214. Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
D Pillay, R Goodall, CF Gilks, D Yirrell, D Gibb, M Spyer, P Kaleebu, P Munderi, C Kityo, A McCormick, J Nkalubo, F Lyagoba, M Chirara, J Hakim
0215. Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
T Bommenel, JL Meynard, O Launay, A Simon, A Mahamat, V Martinez, J Gilquin, C Katlama, AS Lascaux, C Pradier, E Rouveix, D Costagliola, S Abgrall
0222. Major issues and their solutions in the management of HIV and TB — from the laboratory to the patient and population
M Schechter
0223. Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
C Zhang, P Denti, USH Simonsson, G Maartens, MO Karlsson, H McIlleron
0232. HIV therapy in an ageing population — the challenge of polypharmacy
DJ Back
0233. Impact on life expectancy of late diagnosis and treatment of HIV-1 infected individuals: UK CHIC
MT May, M Gompels, CA Sabin
0234. Mitochondrial ageing and antiretroviral therapy exposure
BAI Payne, CA Hateley, DC Samuels, IJ Wilson, M Santibanez-Koref, DA Price, PF Chinnery
0313. Hepatitis C — feedback from the Consensus Conference on the Management of Acute Hepatitis C (AHC) in Paris, May 2010
M Vogel
0314. Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
A Baumgarten, T Lutz, P Kreckel, E Wellmann, U Alshuth, S Mauss, J Rockstroh
0315. The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
J Ashby, LJ Garvey, OW Erlwein, H Lamba, R Weston, K Legg, MO McClure, L Dickinson, A D'Avolio, DJ Back, A Winston
Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe
AS Walker, P Mugyenyi, P Munderi, J Hakim, AA Kekitiinwa, E Katabira, CF Gilks, C Kityo, P Nahirya-Ntege, K Nathoo, D Gibb
Highlights of the 12th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, London, November 2010
M Schambelan
Fatal and non-fatal AIDS and non-AIDS events in HIV-1 infected patients with high CD4 counts
J Reekie, J Gatell, I Yust, E Bakowska, A Rachmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft
Cardiovascular risk assessment in persons with HIV in the developing world: comparing three risk equations in a cohort of HIV-infected Thais
N Edwards-Jackson, SJ Kerr, HV Tieu, J Ananworanich, SM Hammer, K Ruxrungtham, P Phanuphak, A Avihingsanon
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study
JP Viard, JC Souberbielle, O Kirk, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, A Mocroft, JD Lundgren
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
S Rusconi, P Vitiello, F Adorni, E Colella, E Focà, AF Capetti, P Meraviglia, C Abeli, S Bonora, M D'Annunzio, A Di Biagio, A Di Pietro, L Butini, G Orofino, S Farina, G d'Ettorre, D Francisci, A Soria, AR Buonomini, C Tommasi, MP Trotta, M Capasso, E Merlini, GC Marchetti
Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program
A Lazzarin, JG Sierra-Madero, M Battegay, G Mukwaya, R Burnside, D Chapman, J McCracken, S Portsmouth, S Valluri, H Valdez, J Heera
HIV entry blocked by maraviroc can cause an overestimation of viral load
RD Sloan, BD Kuhl, VG Kramer, DA Donahue, T Bar-Magen, R Tressler, MA Wainberg
The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
HJ Stellbrink, S Rugina, C Zagler, S Esser, A Castagna, B Gazzard, A Hill, Y van Delft, S Marks
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients
C Cohen, JM Molina, P Cahn, B Clotet, J Fourie, B Grinsztejn, W Hao, M Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, S Vanveggel, P Williams, K Boven
Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
J Mori, M Westby, M Tawadrous, E van der Ryst, C Charles
Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276)
J Rockstroh, F Felizarta, F Maggiolo, F Pulido, HJ Stellbrink, O Tsybakova, P Yeni, S Almond, C Brothers, I Song, S Min
Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)
J Eron, JM Livrozet, P Morlat, A Lazzarin, C Katlama, T Hawkins, T Fujiwara, R Cuffe, C Vavro, J Santiago, M Ait-Khaled, S Min, JM Yeo
Health-related quality of life and fatigue in HIV-1 infected patients diagnosed during primary versus chronic infection
R Steingrover, MAF Nievaard, JMA Lange, PT Nieuwkerk, JM Prins
The management of acute retroviral syndrome
A Hristea, R Petre, S Gliga, I Olaru, M Ion, R Moroti, C Popescu, R Mihailescu, M Radulescu, V Arama
ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
C Orkin, E DeJesus, H Khanlou, A Stoehr, K Supparatpinyo, T Van de Casteele, E Lathouwers, S Spinosa-Guzman
Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
E DeJesus, A Mills, L Bhatti, C Conner, S Storfer
Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
S Nozza, L Galli, M Di Pietro, F Mazzotta, F Canducci, M Pogliaghi, S Chiappetta, A Galli, V Rusconi, S Salpietro, G Tambussi, A Lazzarin
5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
A Lazzarin, M Johnson, E Ribera, L Weitner, SS Chen, DR Warren
SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
P Kumar, E DeJesus, G Huhn, L Sloan, F Garcia, C Small, H Edelstein, F Felizarta, R Hao, B Ha, B Stancil, L Ross, K Oie, K Pappa
HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
RW Baran, B Dietz, LM Fredrick, M Tian, T Podsadecki
Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
E Billaud, JM Lacombe, A Abgrall, J Ghosn, O Launay, JM Livrozet, JL Meynard, J Pavie, D Costagliola
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa
P Bock, G Fatti, A Grimwood
Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
A Pereira, JP Lopes da Cruz, C Carvalho, C Gonçalves, F Antunes
Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
J van Lunzen, G Fätkenheuer, T Lutz, S Klauke, S Mauss, H Knechten, P Braun, L Gallo, J Goldbach
Reasons for treatment discontinuation in the first year after beginning antiretroviral therapy in a cohort of Portuguese HIV-infected patients
C Caldas, P Andrade, C Azevedo, C Piñeiro, R Serrão, J Soares, R Marques, A Sarmento
Insights into antiretroviral treatment changes in previously naïve patients: results of a Portuguese cohort
C Silva, D Bento, J Rijo, D Alfaiate, I Aldir, C Araújo, H Farinha, K Mansinho
Factors associated with treatment modification during the first year of contemporary HAART
N Martin, I Perez-Valero, B San Jose Valiente, M Mora, JI Bernardino-Serna, J Gonzalez, F Gaya, FX Zamora, JM Pena, JR Arribas
Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS
A Plettenberg, NH Brockmeyer, B Haastert, S Dupke, CK Schewe, M Rausch, M Hower, G Arendt, K Jansen, HIV KompNet
Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
E Merlini, E Sinigaglia, G Carpani, T Bini, A d'Arminio Monforte, GC Marchetti
Immunological response among patients with undetectable viral load followed for 5 years
C Piñeiro, AS Santos, S Cardoso, J Nuak, R Lucas, A Ferreira, S Xerinda, M Tavares, R Marques, A Sarmento
Epidemiological features, therapeutic strategies and long-term immunological outcomes in virologically suppressed HIV+ very late presenters
L Martinelli, D Francisci, A Sgrelli, F Baldelli
Sex matters: retrospective data collection on the date of commencement of ART for HIV-positive women and men in the German KompNet cohort (1991-2009)
I Krznaric, A Wienbreyer, A Zoufaly, P Kreckel, S Esser, T Harrer, K Jansen, C Michalik, S Hertling
Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment
JA Perez-Molina, M Mora-Rillo, I Suarez-Lozano, JL Casado, R Teira, P Rivas, E Pedrol, A Hernando, P Domingo, E Barquilla, H Esteban, J Gonzalez-Garcia
Eligibility for the initiation of HIV treatment in the context of the updated EACS guidelines: results of a clinical audit
MC Aichelburg, M Schlag, A Rieger
Cross-sectional study of HIV living people cohort to specify indications to antiretroviral treatment in naïve patients
AJ Pronin, GD Kaminskiy
Changing antiretrovirals whilst viral load <50 copies/ml and relationship with CD4 count changes
A Mocroft
Influence of demographic and disease parameters on virological response to once- vs twice-daily darunavir/ritonavir (DRV/r) at week 48 in ODIN
M Sension, C Arns Da Cunha, P Domingo, K Supparatpinyo, T Van De Casteele, P De Doncker, F Tomaka
Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
S Spinosa-Guzman, T Van de Casteele, G De La Rosa, P De Doncker
Darunavir in experienced patients
G Sterrantino, B Borchi, M Trotta, D Bartolozzi, F Leoncini
Efficacy and tolerability of darunavir/r 600/100 mg bid in treatment-experienced patients: 48-week data from a German outpatient cohort
J van Lunzen, D Gorriahn, T Wünsche, S Dupke, P Gute, CK Schewe, B Ranneberg
Week 48 efficacy of 900/100 mg daily of darunavir/ritonavir in treatment-experienced HIV-1 patients with virological success: DARDAR study
L Schneider, A Houssaini, S Lambert, G Peytavin, R Agher, A Chermak, P Flandre, V Calvez, AG Marcelin, J Ghosn, C Katlama
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
L Maroldo, LM Fredrick, K Robinson-Morgan, R Trinh, TJ Podsadecki
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
K Jansen, A Sönnerborg, P Pugliese, S Biguenet, JL Eychenne, NH Brockmeyer, C Michalik, S Dupke, H Jaeger, A Plettenberg, D Butcher, MJ Jiménez-Expósito, HIV KompNet
Integrase inhibitor-based treatment in clinical practice
G Cenderello, R Piscopo, M Feasi, G Penco, N Bobbio, G Cassola
Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach
A Grant, Y Kamuntu, P Read, R Kulasegaram
Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
M Doroana, C Piñeiro, F Maltez, P Fonseca, J Oliveira, K Mansinho, A Horta, E Teófilo, M Aguas, I Germano, D Faria
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
JM Llibre, E Martínez, P Barreiro, R Escrig, E Ribera, M Cervantes, A Imaz, F Gutierrez, H Knobel, A Ornelas, FX Zamora, B Clotet
Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
HK Tossonian, JD Raffa, O Alenezi, K Anderson, S Jassemi, K Wight, S DeVlaming, B Conway
Temporal trend of the first prescription of nevirapine: the ANRS CO3 Aquitaine Cohort, 1997-2008
M Bruyand, S Geffard, S Lawson-Ayayi, F Dauchy, G Miremont-Salamé, C Greib, S Farbos, P Morlat, F Dabis
Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
S Landonio, P Meraviglia, AF Capetti, A Di Biagio, S Lo Caputo, G Sterrantino, A Ammassari, B Menzaghi, M Franzetti, G De Socio, G Pellicanò, E Mazzotta, P Zucchi, G Rizzardini
Immunologic impact of maraviroc in clinical practice of a university hospital
S Plata Paniagua, N Trovato Lopez, I Castillo Romera, A Ais Larisgoitia, J Bellon Cano, M Sanjurjo Saez
Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)
J Ghosn, C Delaugerre, A Pinta, N Pierre, D Etienne, F Raffi, L Morand-Joubert
Efficacy of once daily darunavir/ritonavir 800/100 mg in PI/r-experienced HIV-1 infected patients with suppressed HIV-1 replication: the RADAR study
J Ghosn, A Chermak, A Houssaini, G Peytavin, S Lambert-Niclot, N Eychenne, L Slama, A Brunet, C Duvivier, A Simon, AG Marcelin, P Flandre, C Katlama
Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study
V Cooper, R Horne, J Ewan
Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
E Martínez, JA Arranz, D Podzamczer, M Lonca, J Sanz, P Barragán, H Knobel, E Ribera, F Gutierrez, S Valero, B Clotet, D Dalmau, F Segura, JR Arribas, P Barrufet, I Santos, A Payeras, E de Lazzari, J Pich, J Gatell
Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
L Cuzin, C Allavena, L Levy-Bachelot, MA Valantin, H Mellliez, P Pugliese, I Poizot-Martin, C Duvivier, L Finkielsztejn, S Abel
48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)
K Arastéh, A Ward, A Plettenberg, JM Livrozet, C Cordes, A Winston, E Wang, A Quinson
Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
G Le Moal, G Beraud, T Prazuck, L Hocqueloux, A Dupuis, N Venisse
Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
T Baudry, A Boibieux, MC Gagnieu, L Cotte, JM Livrozet, P Miahles, D Makhloufi, C Chidiac, D Peyramond, T Ferry
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
S Bonora, A Calcagno, O Viganò, P Bigliano, S Rusconi, L Trentini, MC Tettoni, G Orofino, B Salassa, C Bramato, A D'Avolio, M Siccardi, E Colella, M Galli, G Di Perri
Switching from tipranavir (TPV) 500/ritonavir (RTV) 200 mg to TPV 500/RTV 100 mg in treatment-experienced patients (pts) with HIV RNA <50 copies/mL
JL Casado, P Domingo, R Rubio, A Antela, MA Lopez-Ruz, A Castro, J Portilla, E Ribera, D Podzamczer, JA Oteo, J Galindo, S Otero, F Lozano, V Estrada, J Moltó, S Moreno
Lopinavir/ritonavir monotherapy in clinical practice
A Caso, E Valencia, V Moreno, M Cervero, J Sanz, R Torres Perea
Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
M Tyrer, L Swaden, NJ Marshall, M Johnson
Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
LJ Garvey, C Higgs, P Mohammed, M Nelson, A Winston
Epidemiological description of the demographic and HIV disease characteristics of HIV patients who are in care but not on treatment in Spain
P Domingo, P Arazo, JL Casado, MA Castaño, E Ferrer, MA Goenaga, R Granados, F Pulido, J Rodriguez, R Rubio, J Sanz, P Viciana
Treatment of HIV-2 infection: a retrospective study from a Portuguese center
N Marques, D Seixas, P Crespo, L Malcata, J Vaz, V Mota, C Morais, J Oliveira, V Duque, J Saraiva da Cunha, A Meliço-Silvestre
The prognosis of patients with dissociated virological and immunological responses to HAART
DJ Jevtovic, DR Salemovic, JT Ranin
Prediction of virological failure in HIV-infected individuals treated with cART in Suriname
MP Bleijenberg, WFW Bierman, C Jaglall, MW Heymans, MC ten Doesschate, PT Nieuwkerk, PH Smits, M van Eer, S Vreden
British HIV and ageing study. HIV and ageing: older people with HIV, who are they?
S Allan, RA Daly, Y Yoganathan, S Barrett, A Joseph, A Tariq, CW Saing, C Williams, C Lane, J Sikorska
A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
R Qaqish, J van Wyk, MS King
Abstract withdrawn
Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
A Avihingsanon, T Apornpong, SJ Kerr, J Ananworanich, K Ruxrungtham
Immune impairment and adaptive response in relation to antiretroviral therapy of HIV-infection
GD Kaminskiy, AJ Pronin
Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
D Francisci, E Falcinelli, B Belfiori, E Petito, M Mezzasoma, F Baldelli, P Gresele
Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy
R Palacios, JA González-Correa, J Ruiz, E Nuño, M Márquez, JP de la Cruz, J Santos
Cardiovascular risk in patients visiting the Hadassah AIDS Center, Jerusalem
S Schulman, V Rotshild, K Olshtein Pops, M Korem, S Israel, M Hauzi, S Maayan
Incidence of ischemic cardiovascular events in the maraviroc clinical development program
S Portsmouth, R Burnside, A Lazzarin, M Johnson, H Valdez
Low serum phosphate levels are related to increased cardiovascular risk in HIV-1 infected patients
P Grima, M Guido, R Chiavaroli, P Tundo, A Zizza
Prevalence of cardiovascular risk factors in Spanish HIV-1-infected male inmates
JP Golf, L Sala, J Aramburo, P Sardà, N Perez-Alvarez, JM Llibre
Nitric oxide protects against HIV gp120 endothelial injury
S Fiorucci, A Mencarelli, D Francisci, E Distrutti, B Renga, F Baldelli
Higher red blood cell distribution width is associated with a worse virologic and clinical situation in HIV-infected patients
S Puerta, M Gallego, R Palacios, J Ruiz, E Nuño, M Márquez, J Santos
Alexithymia, an impairment of emotional cognitive processing, is a candidate risk factor for carotid artery plaque formation in HIV-infected patients
F Vadini, F Sozio, E Mazzotta, C Agostinone, T Ursini, A Agostinone, G Placido, LM Manzoli, G Parruti
Lipodystrophy and metabolic syndrome in Romanian HIV-infected adults
M Arbune
Mesenteric fat thickness in a group of HIV patients on HAART
SS Lee, E Liu, KW To
Hypertriglyceridemic waist identifies HIV+ men and women at increased cardiometabolic risk
G Guaraldi, S Zona, G Orlando, F Carli, C Stentarelli, J Despres, R Ross
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
T Overton, JA Aberg, S Gupta, R Ryan, B Baugh, G De La Rosa
Adiponectin and leptin levels in HIV-infected patients with lipodystrophy in Southern India
S Mini Jacob, K Annie Phoebe, R Hemalatha, MR Sivakumar, MP Ravindran, MV Natarajan
Nutritional status in HIV-infected patients using Changi's mini nutritional assessment
M Cervero, V Alcázar, R Sanz, C García-La Calle, JL Agud
Dietician-based approach to lipodystrophic syndrome: role of bioelectrical impedance analysis at week 12
G Orofino, M Guastavigna, P Martinoglio, D Penoncelli, D Demarie, M Tettoni, P Desiderato, R Di Frenna, C Zignin
Altered phosphate metabolism in HIV-1-infected patients: another feature of metabolic syndrome?
P Grima, A Zizza, M Guido, P Calabrese, R Chiavaroli, MR Sodo, M Tana, P Tundo
Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study)
JM Rodriguez, M Delgado, P Viciana, MA Lopez-Ruz, M Leal, F Alcacer, E Deig, A Antela, E Pedrol, S Moreno
Switching from Kivexa + efavirenz to Atripla reduces total cholesterol in hypercholesterolemic subjects: final results of a 24-week, randomized study
G Moyle, C Orkin, M Fisher, J Anderson, J Dhar, MH Wang, J Ewan
CD4 response, lipid changes and liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years
D Podzamczer, JM Tiraboschi, J Mallolas, MA Cárdenes, E Casas, A Castro, S Echevarria, M Leal, JC Lopez Bernanldo de Quirós, S Moreno, T Puig, E Ribera, C Villalonga, JL Gomez Sirvent, JA Garcia Heranejos, J Lopez-Aldeguer, P Barrufet, L Force, I Santos, J Sanz
Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA
L Ryom, A Mocroft, P Reiss, B Ledergerber, S De Wit, D Duiculescu, AD Monforte, M Murphy, JD Lundgren, O Kirk
Kidney tubular function and serum phosphate levels in HIV-1-infected patients treated with tenofovir: preliminary results
P Grima, A Zizza, P Calabrese, R Chiavaroli, A Faraone, M Tana, MR Sodo, P Tundo, M Guido
Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART
A Uglietti, C Gervasoni, E Gabrielli, S Di Giambenedetto, R Cauda, R Esposito, P Grima, G Di Perri, R Maserati, M Galli
A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
I Izzo, L Albini, A Calabresi, D Motta, R Bellagamba, R Fezza, P Narciso, L Sighinolfi, P Maggi, E Focà, M Mendeni, L Manili, M Magoni, G Carosi, E Quiros-Roldan, C Torti
The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
I Cassetti, A Etzel, JV Madruga, JM Suleiman, Y Zhou, M Rhee, DR Warren
Intracellular tenofovir-diphosphate accumulation in an HIV-infected patient with Fanconi syndrome and osteomalacia
ME Haverkort, BW van der Spek, PT Lips, WAT Slieker, W Bronsveld
The association between metabolic syndrome and the occurrence of nephrolithiasis in HIV-infected patients
IM Dumitru, S Rugina, G Sotila, E Dumitru, CN Rugina
Prevalence of chronic renal failure stage 3 or more in HIV-infected patients in Antwerp: an observational study
AW Colson, E Florence, H Augustijn, GA Verpooten, L Lynen, E Gheuens
Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
W Mankhatitham, A Lueangniyomkul, W Manosuthi
Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
J Macías, J Mallolas, LF López-Cortés, JA Cartón, P Domingo, S Moreno, JA Iribarren, K Neukam, A Rodrigo, MJ Jiménez-Expósito, JA Pineda
Liver fibrosis: concordance analysis between APRI and FIB-4 scores, evolution and predictors in a cohort of HIV patients without HCV and HBV infection
M Mendeni, E Focà, D Gotti, N Ladisa, E Quiros-Roldan, A Vavassori, F Castelnuovo, G Carosi, G Angarano, C Torti
Clinical significance of hyperbilirubinemia in the CASTLE study
J Uy, W Hu, V Wirtz, T Hosey, D Butcher, D McGrath, A Farajallah
A case of nodular regenerative hyperplasia in a patient who had been taking didanosine
C Jackson, R Fox, M Priest, D Clutterbuck, E Peters
Toxic intracellular anabolite levels of tenofovir and didanosine causing a steep CD4-cell decline
E de Jong, ME Haverkort, R ter Heine, RS Jansen, JH Beijnen, MA van Agtmael
Lack of association between mitochondrial DNA polymorphisms and didexoxynucleoside-induced hyperlactataemia in black-African, HIV-1-infected patients
A Arenas-Pinto, I Weller, R Ekong, A Grant, A Karstaedt, L Telisinghe, M Bolhaar, S Charalambous, N Bradman, C Ingram
Markers of bone turnover are elevated in patients on antiretrovirals independent of the substance used
RJ Piso, M Rothen, JP Rothen, M Stahl
Quantitative ultrasound (QUS) in HIV-infected patients: a reliable and low-cost technique for bone health assessment
R Marocco, H Martini, V Belvisi, T Tieghi, R Cesareo, C Del Borgo, M Lichtner, CM Mastroianni
Fracture risk in HIV and the need for guidelines: the Probono-1 Trial
B Peters, H Isohanni, S Tillet, F Ibrahim, G Hampson, FMK Williams, MEO Perry, A Duncan, A Wierzbicki
Rates of bone fractures in a cohort of HIV-infected adults in the UK
A Samarawickrama, R Malik, M Fisher, Y Gilleece, K Walker-Bone
Prevalence of vitamin D deficiency: cross-sectional study of a hospital cohort of HIV-1 infected outpatients
M Cervero, V Alcázar, C García-La Calle, R Sanz, JL Agud
The serum level of 25-OH vitamin D and Th1 cytokine pattern in HIV infection versus hepatitis C virus infection and hepatitis B virus infection
SA Iacob, D Banica, E Panaitescu, M Cojocaru, D Iacob
Prevalence and factors associated with severe vitamin D deficiency in HIV/hepatitis C co-infected patients
S Surah, A Samarawickrama, L Campbell, R Kulasegaram, F Post, M Fisher, B Peters, J Fox
Tenofovir use is associated with low vitamin D levels in a Spanish HIV cohort
M Cervero, C García Lacalle, JL Agud, R Torres Perea, E García-Benaya, J Jusdado, C Pérez Pons, M del Álamo
Safety and efficacy of maraviroc (MVC) combined with multiple different therapeutic agents in highly treatment-experienced (TE) patients in Brazil
JJD Furtado, JV Madruga, EL Bicudo, M Eira, MIB Lopes, EM Netto, MS de Oliveira, OHM Leite, AA Machado, U Tupinambas, JL de Andrade Neto, MPJ Lima, DB Wajsbrot, LM Cassoli
Behaviour and attitudes in HIV (BEAHIV): a national survey study to examine the level of agreement between physicians and patients in symptom reporting
A Rachlis, J Gill, M Harris, J Macleod, C Worthington, J Brunetta, A Tsang, H Hew, J Leith, F Camacho, D Turner, C Fraser
Continuing burden of HIV late presenters in the North East of England 2009
N Premchand, K Golds, PY Tan, I Bittiner, N Sanker, ELC Ong
Drug interactions in the elderly HIV-infected patient
C Coroiu, F Tollinchi, G Hittinger, S Mokhtari, P Granet, O Faucher-Zaegel, A Madrid, A Menard, JL Mattei, S Chadapaud
Sexual dysfunction and anxiety in HIV-1-infected males in Eastern Sicily
BM Celesia, C Coco, F Bisicchia, G Pellicanò, MT Mughini, F Palermo, G Nunnari, R Russo
Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety
MEO Perry, N Almaani, N Desai, J Fox, N Larbalestier, D Chilton
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
G Madeddu, V Soddu, E Ricci, T Quirino, B Menzaghi, C Bellacosa, C Grosso, S Melzi, L Valsecchi, M Franzetti, F Vichi, G Penco, A Di Biagbio, G Pellicanò, L Corsico, GVL De Socio, E Mazzotta, G Parruti, M Guastavigna, G Orofino, MS Mura, P Bonfanti
Efavirenz use and contraceptive methods in HIV-positive women in a large urban cohort
RA Seaton, R Fox, A MacConnachie, P Anderson, R Nandwani, E Peters, A Winter, R Taylor
Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
S Esker, J Albano, H Tilson, J Uy, D Arikan, K Krantz, MJ Jiménez-Expósito, D Seekins
Administration of darunavir tablets in patients with difficulties in swallowing – two case reports
S Scholten, S Mauruschat, S Hindermann, B Ranneberg
Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?
K Seden, DJ Back, SH Khoo
Adherence, quality of life and number of daily pills in a large cross-sectional study
N Gianotti, L Galli, B Bocchiola, T Cahua, P Panzini, D Zandonà, S Salpietro, M Maillard, A Danise, A Pazzi, A Lazzarin, A Castagna
Changing HIV guidelines: how to communicate treatment start
J Fehr, D Nicca, W Langewitz, D Haerry, M Battegay
Relating protease inhibitor resistance at time of virological failure with drug exposure
M Van Luin, WP Bannister, R Paredes, AN Phillips, J Bruun, J Van Lunzen, O Kirk, A d'Arminio Monforte, A Cozzi-Lepri, DM Burger
Does feedback of medication execution using MEMS caps aid adherence to HAART?: the MEMRI study (MEMS as Realistic Intervention)
S Davies, S Asghar, V Cooper, A Lange, C Robertson, B Vrijens, DJ White
Antiretroviral regimen complexity as a predictor of adherence
C Boyle, A Wilson, G Treacy, G Sheehan, J Lambert, C Meegan, P Mallon
Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
I Perez-Valero, N Martin, B Jose Jose Valiente, JI Bernardino-Serna, M Mora, F Gaya, J Gonzalez, FX Zamora, JM Pena, JR Arribas
High level of adherence to HAART among refugees and internally displaced persons on HAART in western equatorial region of Southern Sudan
O Salami, A Buzu, C Nzeme
Identifying causes of loss to follow up in newly diagnosed HIV-infected patients
V Fridman, NS Bello, MB Lasala
Transmitted drug resistance associated with transmission clusters in newly diagnosed antiretroviral-naïve patients in Northern Greece
L Skoura, S Metallidis, AJ Buckton, JL Mbisa, D Pilalas, E Papadimitriou, A Papoutsi, AB Haidich, D Valagouti, O Tsachouridou, ZA Antoniadou, P Kollaras, P Nikolaidis, N Malisiovas
Analysis of transmitted drug resistance, resistance mutations and future antiretroviral efficacy in HIV-1 subtype F infected-patients prior to therapy
LSC Manolescu, CM Sultana, C Vagu, A Temereanca, SM Ruta
Detection of HIV type 1 mutations on the pol region in untreated patients in Northern Vietnam: determination of drug resistance and subtypes
S Ranger-Rogez, M Al Jawhari, B Nguyen, N Pham Hong, T Tran Quoc, J Pascual, J Doll, M Harzic, G Viretto, P Weinbreck
Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study
S Portsmouth, S Valluri, M Daeumer, B Thiele, H Valdez, M Lewis, C Craig, A Thielen, I James, J Demarest, J Heera
Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
MJ Obermeier, A Carganico, S Dupke, D Schranz, C Cordes, M Freiwald, G Klausen, S Köppe, C Schuler, C Mayr, D Schleehauf, T Berg, I Krznaric, A Baumgarten
Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
J Rockstroh, J Eron, D Cooper, R Steigbigel, BY Nguyen, X Xu, H Wan, A Rodgers, M Miller, R Leavitt, P Sklar, H Teppler
Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
F Pulido, JR Arribas, A Hill, Y van Delft, C Moecklinghoff
Changing prevalence of darunavir resistance-associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003-2009
G De La Rosa, T Pattery, G Picchio, E Lathouwers, J Villacian, K Van der Borght
Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
AG Marcelin, C Charpentier, M Wirden, D Descamps, V Calvez
Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis
A Zolopa, W Towner, A Lazzarin, G Fätkenheuer, D Butcher, J Uy
High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
N Mantovani Pena, R Gonçalves Azevedo, D Funayama Castro, R Sobhie Diaz, S Vasconcelos Komninakis
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
AG Marcelin, C Charpentier, C Ferreira, M Wirden, C Lemarchand, D Descamps, V Calvez
Abstract withdrawn
Is extended resistance to the historical antiretroviral drugs & drug classes still a risk factor for HIV progression?
M Zaccarelli, P Lorenzini, P Marconi, F Forbici, C Gori, P Sette, F Ceccherini-Silberstein, P Narciso, CF Perno, A Antinori
Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy
JE Gaytán-Martínez, JA Mata-Marín, F Gutierrez-Escolano, L Pérez-Saleme, S Treviño-Pérez, JG Vázquez-Rosales, N Matías-Juan, RD Díaz-Ramos, R Arias-Flores
HIV drug resistance in children with treatment failure to first-line regimens in Ho Chi Minh City, Vietnam
VTT Nhung, D Colby, TH Khanh, TT Viet, D Lu, HT Thuy, B An, LT Giang
Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009)
L Pérez, J Aleman, C Correa, J Pérez, C Fonseca, C Aragones, D Pérez, A Alvarez, AM Vandamme, V Kourí, K Van Laethem
Development of drug resistance among HIV-1 F1 sub-type patients with treatment failure
A Temereanca, CM Sultana, L Manolescu, C Vagu, C Grancea, S Ruta
Pro-viral DNA and antiretroviral treatment simplification
D Zucman, C Rouzioux, V Avettand-Fenoel
Haemoglobin and anaemia in the SMART study
A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, M Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips
Genotype testing in HIV-infected pregnant women
C Afonso, A Zagalo, N Janeiro, F Antunes
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece
P Panagopoulos, D Paraskevis, V Sypsa, M Detsika, K Protopapas, V Sakka, G Poulakou, A Papadopoulos, G Petrikkos, A Hatzakis
Feasibility of testing antibodies to HIV from filter paper using HIV rapid test kits
A Ganesan, G Thatchinamoorthy, S Saramini
Effect of lipemia and bilirubinemia on HIV-1 protease and reverse transcriptase genotyping and phenotyping success: a five-year analysis
T Pattery, A Van Cauwenberge, M Van Hove, V Smits, K Van Soom, J Villacian
Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
D Fox, R O’Connor, P Mallon, G McMahon
Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
P Wikman, P Safont, MJ Perez-Elías, A Moreno, F Dronda, S Moreno, JL Casado
CCR5 D32 modifies 15-year mortality risk associated with well-established clinical and immunological factors among HIV-infected patients
M Parczewski, M Leszczyszyn-Pynka, D Bander, A Urbañska, M Kaczmarczyk, S Ciechanowicz, A Boron-Kaczmarska
What drives a normal relation between T-CD4 and T-CD8?
R Badura, RJG Antunes, N Janeiro, C Afonso, F Antunes
Comparative evaluation of ARV therapy efficiency among patients at the Kiev regional AIDS center
YO Yurchenko, T Stepchenkova, KI Karnets, MO Martinenko
Feasibility and effectiveness of combination antiretroviral therapy in HIV-infected infants in Pietermaritzburg, South Africa
D Van der Linden, S Purchase, NH McKerrow
Promoting presumptive diagnosis of severe HIV disease to increase uptake of antiretroviral therapy in HIV-infected infants
J Chiwoko, E Mhango, S Phiri, R Weigel
Audit of outcomes of early initiation of antiretroviral therapy in children admitted to the paediatric wards at Kilifi district hospital, Kenya
HM Nabwera, S Mwaringa, R Kimutai, JA Berkley
Salvage therapy with raltegravir in a 3-month-old infant
AB Brolund, C Ilchmann, R Ganschow, O Degen
High preterm delivery rates associated with initiation of HAART during pregnancy
GP Taylor, M Douglas, J Smith
Minority M184V variants in women exposed to 3TC/FTC-containing lopinavir-ritonavir (LPVr) regimens in pregnancy
S Surah, S Oshea, S Costelloe, M Hanlon, J Mullen, I Chrystie, GP Taylor, A De Ruiter
Antiretroviral strategies for the treatment of pregnant HIV+ women and prevention of perinatal HIV transmission in Dodoma, Tanzania: AMANI Study
G Liuzzi, F Vairo, Z Chaula, B Nguhuni, E Nicastri, N Bevilacqua, A Cannas, MG Paglia, G Ippolito
Use of antiretroviral therapy during pregnancy among HIV-infected women attending an urban care centre
F Ssewankambo, C Nalugwa, J Sempa, J Walusimbi, A Kambugu
A complex of measures effectiveness in reducing mother-to-child HIV transmission
SV Minaeva, GF Moshkovich
Amniocentesis is a low-risk procedure in HIV-treated pregnant women
MM Simoes, CO Marques, F Albergaria, C Guerreiro, A Pereira, J Correia, J Castela
Pregnancy decisions and contraceptive use among HIV-positive women: a study in a large urban clinic in sub-Saharan Africa
J Walusimbi, E Birabwa, E Nabankema, A AnneMarie, I Lutalo, A Nakiwooga
A method to estimate the number of people in a country or region with HIV who are undiagnosed and in need of ART
RK Lodwick, CA Sabin, AN Phillips
Older HIV-infected individuals present late and have a higher mortality: a UK clinic cohort study
CC Iwuji, D Pao, Y Gilleece, M Fisher, D Churchill
Offering HIV testing in an emergency admission unit in Newcastle upon Tyne, UK — a pilot audit study
S Ellis, L Graham, DA Price, ELC Ong
A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden
J Brännström, V Svedhem, A Yilmaz, A Blaxhult, S Wendahl, A Sönnerborg
Audit of telephone HIV clinics: effective and acceptable
WFC Woolley, C Babu, A Sukthankar, O McQuillan
Newly diagnosed HIV patients in Lima, Peru: a comparison of individuals diagnosed through an intervention program versus self-referred individuals
JA Hidalgo, N Castillo, C Agurto
Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia
M Bloch, J Hoy, N Cunningham, N Roth, N Andrianopoulos, C Rayner, A Carr
Five-year outcomes of HAART at a non-governmental treatment center in Lima, Peru
N Castillo, C Agurto, C Benites, JA Hidalgo
The impact of late presentation: analysis of a cohort of 313 Portuguese patients
D Alfaiate, AC Miranda, J Rijo, D Fernandes, F Borges, H Farinha, K Mansinho
T-CD4+ cell count at the date of the HIV diagnosis
AR Domingues da Silva, J Mendez, R Sarmento e Castro
Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
PK Gitta, L Kendall, V Musiime, K Adkison, AA Kekitiinwa, A Ferrier, O Opilo, Y Lou, MF Bwakura-Dangarembi, P Nahirya-Ntege, S Bakeera-Kitaka, M Ssenyonga, W Snowden, D Burger, AS Walker, D Gibb
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
LJ Else, V Jackson, M Brennan, J Breiden, C Weldridge, S Coulter-Smith, DJ Back, SH Khoo, J Lambert
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
M Siccardi, A D'Avolio, L Baietto, M Simiele, S Bonora, DJ Back, G Di Perri, A Owen
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
A Calcagno, MG Milia, A D'Avolio, P Ndayishimiyae, P Dusabimana, S Bonora, J Cusato, M Simiele, R Rostagno, M Siccardi, S Audagnotto, V Ghisetti, G Di Perri
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100, 200/150, and 200/50 mg twice daily in HIV-negative volunteers
AGA Jackson, A Hill, LJ Else, DJ Back, R Morley, R Puls, J Amin, E Lin, M Boffito
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi
L Dickinson, M Chaponda, D Carr, JJ van Oosterhout, J Kumwenda, DG Lalloo, M Pirmohamed, R Heyderman, SH Khoo
PK/PD modeling supports the dose-escalation decision in VIKING
M Lovern, M Underwood, G Nichols, I Song
Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
Y Zhang, A Owen, D Egan, SF Sarfo
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
L Dickinson, AGA Jackson, LJ Garvey, V Watson, SH Khoo, A Winston, M Boffito, GR Davies, DJ Back
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
V Sekar, G De La Rosa, T Van de Casteele, S Spinosa-Guzman, P Vis, RMW Hoetelmans
Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE
HM Crauwels, E van Schaick, RPG van Heeswijk, S Vanveggel, K Boven, P Vis
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
J Moltó, M Valle, C Miranda, S Cedeño, E Negredo, MJ Barbanoj, B Clotet
Moringa oleifera supplementation by patients on antiretroviral therapy
TG Monera, CC Maponga
The use of a darunavir/ritonavir once-daily regimen in two pregnant women
JS Lambert, LJ Else, V Jackson, L Dickinson, DJ Back, M Brennan, C Weldridge, S Coulter-Smith, S Gibbons, SH Khoo
Treatment of chronic invasive fungal sinusitis with voriconazole in an HIV patient
A Ho, G McGarry, E Peters
Opportunistic infections (OIs) present in HIV-seropositive patients: a study
K Ayodhya Ramaiah, B Sudha Rani, R Anand, S Ramola, P Satish Babu, R Ramesh Babu
Immunological diagnosis of CMV infection in HIV-infected patients
IM Dumitru, S Rugina, E Dumitru, RC Cernat, S Diaconu, C Maxim Mitroi
Epidemiology of HIV-associated tuberculosis (TB) co-infection in Krasnoyarsk region, Russian Federation
TA Chaychuk, NU Gankina, OG Nikonova
A minority of tuberculosis cases occurring during HIV care is possibly preventable
L Skeie, T Skrede, A Maeland
Generalized tuberculosis in HIV-infected patients with AIDS
VN Zimina, IA Vasilieva, AV Kravchenko, FA Batyrov
Therapy of the patients with HIV/TB infection and dynamics of level 'naïve' CD4-lymphocytes
AA Popova, AV Kravchenko, GM Kozhevnikova, LV Serebrovskaya
Enfuvirtide in therapy at patients with HIV-infection and tuberculosis
AV Kravchenko, AV Kuznetsova, OA Kozyrev, VA Lukyanova, VG Kanestri
Sudden unexplained death in a patient with HIV and MDR-TB
E Boxall, J Milne, E Peters, C Sykes
Hepatitis C virus (HCV) infection and re-infection among HCV- and HIV/HCV-infected injection drug users
B Conway, A Barrieshee, HK Tossonian, K Wight, S Jassemi, M Tong, E Knight, L Gallagher, F Duncan, S DeVlaming
Increasing numbers of acute hepatitis C infections in HIV-infected MSM and high reinfection rates following SVR
HJ Stellbrink, CK Schewe, M Vogel, C Noah
High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México
JA Mata-Marín, JE Gaytán-Martínez, CI Arroyo-Anduiza, G Calderón-Rodriguez
Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the 'real-life setting' proves the concept
P Ingiliz, MJ Obermeier, L Weitner, C Cordes, A Moll, B Hintsche, F Schlote, S Köppe, C Mayr, A Baumgarten
Correlates of hepatic stiffness by FibroScan© in a multicentric Italian cohort of HIV-infected patients
P Tarquini, F Sozio, E Marchionni, E Gabrielli, E Polilli, F Ancarani, D Di Giammartino, LM Manzoli, G Parruti
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients
S Ferrara, A Tartaglia, T Santantonio, B Grisorio
Do interleukin-28B single nucleotide polymorphisms influence the natural history of chronic hepatitis B?
L Martín-Carbonero, NI Rallón, JM Benito, E Poveda, J González-Lahoz, V Soriano
No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
JV Fernández-Montero, L Martín-Carbonero, P Barreiro, NI Rallón, JM Benito, J González-Lahoz, V Soriano
Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
JA Mata-Marín, CI Arroyo-Anduiza, R Arias-Flores, JE Gaytán-Martínez
Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
P Labarga, ME Vispo, JM Guardiola, C Miralles, L Martín-Carbonero, J Portu, P Barreiro, P Miralles, J Morello, MJ Tellez, P Bancalero, V Asensi, NI Rallón, I Santos, L Morano, K Aguirrebengoa, MJ Rios, R Rubio, K Neukam, J González-Lahoz, V Soriano
Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART
SP Tsarenko, AV Kravchenko, VG Kanestri, SL Maximov
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials
M Nelson, G Amaya, N Clumeck, C Arns Da Cunha, D Jayaweera, P Junod, L Taisheng, P Tebas, M Stevens, A Buelens, S Vanveggel, K Boven
Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
L Bhatti, S Shah, H Khanlou
Efficiency of HIV-1 PR-RT genotyping is not impacted by co-infection with HCV
ACA Deloof, H De Wolf, Y Verlinden, J Villacian, T Pattery
Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era
AM Cattelan, M Zanchetta, L Sasset, R Petrara, R Freguja, K Gianesin, MG Cecchetto, F Cremona, A De Rossi
Abstract withdrawn
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
A Cingolani, L Torti, C Pinnetti, K de Gaetano Donatil, R Murri, E Tacconelli, LM Larocca, L Teofili
Cancer chemotherapy: early experience with combined chemotherapy for HIV-infected Kaposi's sarcoma patients at Lighthouse clinic, Lilongwe, Malawi
HF Mulinde, H Tweya, J Chiwoko, C Feldacker, S Phiri, M Nyirenda, R Weigel, L Mlundira
Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
MO Onigbogi, OY Ojo
Review of HIV testing at a district general hospital in an area of high HIV prevalence following the introduction of new national guidelines
ID Page, M Phillips, P Flegg, R Palmer
HIV testing in non-traditional settings: feasibility and acceptability in an acute admissions unit
R Cridford, A Thornton, M Rayment, S Mguni, D Millett, S Mandalia, A Nardone, M Tenant-Flowers, A Sullivan, R Ghosh, J Anderson
Clinical profile of HIV/AIDS patients admitted to a tertiary outpatient clinic in Istanbul, Turkey
O Aydin Altuntas, H Kumbasar Karaosmanoglu, R Korkusuz, O Nazlican
Aetiologies and factors associated with mortality among HIV-infected patients at Taraba State Specialist Hospital, Jalingo, Nigeria
DR Dashe
Causes of death in patients infected with HIV from 1985 to 2008
J Mendez, R Sarmento e Castro, AR Domingues da Silva
Syphilis infection is associated with an increase in plasma viral load in HIV infected patients: results from the FHDH cohort — ANRS CO4
W Jarzebowski, C Piketty, P de Truchis, E Caumes, D Farhi, AS Lascaux, MA Bouldouyre, O Derradji, J Pacanowski, N Dupin, D Costagliola, S Grabar
Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
H Lagler, K Grabmeier-Pfistershammer, V Touzeau-Römer, S Tobudic, A Rieger, H Burgmann
No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
M Vourvahis, R Wong, NM Ndongo, M O'Gorman, M Tawadrous
Leukocyte extract reduces HIV replication and modulates cellular factors involved in HIV infection: therapeutic meant
C Fernandez-Ortega, D Casillas, M Dubed, L Navea, A Ramirez, L Lopez, T Paneque, Y Reinoso
Therapeutics designed to neutralize soluble HIV tat protein could preserve IL-7 signaling and CD8 T-cell function in HIV+ patients
EM Faller, SM Sugden, PA MacPherson
Novel monitoring technique to minimise the risk for patients participating in pilot studies of investigational compounds
R Cuffe, M Ait-Khaled, S Hughes, S Min, G Nichols, D Thomas, M Underwood, JM Yeo
Abstract withdrawn
Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects
L Galli, S Salpietro, G Pellicciotta, A Galliani, PM Piatti, H Hasson, M Guffanti, N Gianotti, A Bigoloni, A Lazzarin, A Castagna
Smoking prevalence, cessation rates and relapse rates in the Swiss HIV Cohort Study (SHCS)
M Huber, B Ledergerber, R Jaccard, L Elzi, H Furrer, B Hirschel, M Cavassini, E Bernasconi, P Schmid, R Weber
Prevalence and risk factors for chronic obstructive lung disease in HIV-infected patients in the HAART era
G Madeddu, AG Fois, GM Calia, F Becciu, B Piras, ML Fiori, V Spada, C Lovigu, M Mannazzu, P Pirina, MS Mura
High plasma levels of parathyroid hormone (PTH) are associated with an increased cardiovascular risk among HIV-infected subjects
V Spagnuolo, L Galli, S Salpietro, C Vinci, F Cossarini, G Travi, A Rubinacci, G Mignogna, M Cernuschi, S Bossolasco, A Lazzarin, A Castagna
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
MS Broder, T Juday, J Uy, EY Chang, TGK Bentley
Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices
JR Arribas, A Hill, I Garcia, A Anceau
Late versus non-late presentation of HIV/AIDS: an economic impact analysis
K Grabmeier-Pfistershammer, A Rieger, T Schroeck, M Schlag
Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
F Aragão, I Vaz Pinto, J Vera